Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

Study could provide potential therapeutic strategies for treating prostate cancer

Prostate cancer cells are more likely to spread to other parts of the body if a specific gene quits functioning normally, according to new data from researchers at UT Southwestern Medical Center.

3 Feb 2010

EpiCept regains compliance with Nasdaq minimum bid price requirement

EpiCept Corporation today announced that Nasdaq notified the Company that it has regained compliance with the minimum bid price requirement in Listing Rule 5550(a)(2) and met the requirements of the Nasdaq Listing Qualification Panel (the “Panel”) decision dated November 2, 2009. Accordingly, the Panel has determined to continue the listing of the Company’s common stock on The Nasdaq Stock Market.

3 Feb 2010

VIDAZA prolongs survival in AML patients

The Myelodysplastic Syndromes (MDS) Foundation says a study published this week in the Journal of Clinical Oncology concludes VIDAZA (azacitidine) “prolongs survival and is well tolerated” in patients with acute myeloid leukemia (AML) - an aggressive form of leukemia that in many cases progresses from MDS.

3 Feb 2010

GenSpera’s G-115 anti-cancer drug awarded US patent

GenSpera, Inc. announced that its patent application, entitled “Tumor Activated Prodrugs,” has been issued by the United States Patent and Trademark Office (USPTO) as US Patent 7,635,682. The patent covers the composition and potential uses of G-115, GenSpera’s second anti-cancer drug in development.

2 Feb 2010

Gentag signs license agreement to develop and commercialize post surgery wireless skin patch

Gentag, Inc. and The CORE Institute® are pleased to announce the signing of a license agreement to develop and commercialize a disposable wireless skin patch to allow patients to self monitor themselves in the comfort of their homes after orthopedic surgery in hospitals through the use of cell phones

2 Feb 2010

Vantia Therapeutics initiates Phase IIb trial of VA106483 for nocturia

Vantia Therapeutics, an emerging pharmaceutical company developing novel, small molecule drugs targeting large, underserved medical markets, today announces it has begun its planned Phase IIb trial of its lead development compound VA106483 for nocturia.

2 Feb 2010

RECOTHROM topical hemostat exhibits low rate of anti-product antibody formation

ZymoGenetics, Inc., today announced the publication of pooled safety and immunogenicity observations from eight clinical trials of RECOTHROM in the February issue of the Journal of the American College of Surgeons. The authors concluded that RECOTHROM is a well-tolerated topical hemostatic agent in numerous surgical settings and has a low rate of anti-product antibody formation. In the pooled data from all trials, less than one percent of treated patients developed product-specific antibodies. None of the antibodies neutralized native coagulation proteins.

2 Feb 2010

Cytheris broadens patent protection for recombinant human interleukin-7

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for its patent application "Glycosylated IL-7, Preparation and Uses", US Patent Application Number 11/996,176. The Notice of Allowance is the USPTO’s official communication that the Company’s application has successfully completed examination and that a patent will be issued.

2 Feb 2010

Spectrum Pharmaceuticals signs co-development and commercialization agreement with TopoTarget A/S

Spectrum Pharmaceuticals, a commercial-stage biotechnology company with a primary focus in oncology, today announced that it has entered into a co-development and commercialization agreement with TopoTarget A/S for Belinostat, a novel histone deacetylase (HDAC) inhibitor.

2 Feb 2010

MDLinx announces new Omnibus offering for international pharmaceutical market research

MDLinx, a division of M3 USA, announced today a new Omnibus offering for international pharmaceutical market research. The new offering, launched at the Pharmaceutical Market Research Conference, enables market researchers a new, simplified, reduced-cost means of accessing specialty physicians around the world.

2 Feb 2010

ADT can worsen heart risk factors and may increase the risk of heart attack

Androgen-deprivation therapy (ADT), commonly used to treat prostate cancer, can worsen heart risk factors and may increase the risk of heart attack and/or cardiac death, although the relationship between ADT and heart attack or cardiac death has not been definitively established, according to a science advisory published in Circulation: Journal of the American Heart Association and CA: A Cancer Journal for Clinicians.

2 Feb 2010

BRI partners with French Government to create therapeutic antibodies for treatment of major diseases

"We are delighted to be working with such esteemed institutions in order to generate cutting-edge therapeutic antibodies," said Matthew Baker, chief scientific officer and co-founder of Antitope. "This agreement combines our partners' expertise in novel therapeutic strategies with Antitope's expertise in engineering humanized antibodies to create therapeutic antibodies that may have a significant impact on the treatment of these major diseases."

2 Feb 2010

IMRT and extensive safety measures can prevent radiation injuries in cancer patients, says oncology expert

Recent media stories have reported isolated cases of cancer patients who were injured by incorrect doses from intensity-modulated radiation therapy (IMRT).

2 Feb 2010

Cephalon to acquire Swiss-based pharmaceutical company

Cephalon, Inc. (Nasdaq: CEPH) announced today that it has signed an agreement to acquire Mepha AG and its subsidiaries, a profitable, privately-held, Swiss-based pharmaceutical company.

1 Feb 2010

Abbott signs licensing agreement with Pierre Fabre SA to develop and commercialize cancer antibody h224G11

Abbott announced today an exclusive worldwide licensing agreement with Pierre Fabre SA to develop and commercialize h224G11, a pre-clinical monoclonal antibody identified at the Centre d'Immunologie Pierre Fabre (CIPF) in France and targeting the cMet receptor for the treatment of cancer.

1 Feb 2010

Managing Myeloma reviews past accomplishments; discusses future goals in evolving therapeutic landscape

Managing Myeloma (www.ManagingMyeloma.com) convened the 2010 Multidisciplinary Advisory Board on January 16, 2010 to review the past 18 months and discuss the educational and practical needs of myeloma practitioners in an evolving therapeutic landscape.

1 Feb 2010

Asuragen enters into research agreements to develop microRNA-based diagnostic test

Asuragen, Inc., a leader in molecular diagnostics and RNA-based pharmacogenomics services, announced today that it has entered into research agreements with The University of Pittsburgh Medical Center, Brigham and Women’s Hospital, the H. Lee Moffitt Cancer Center, Dartmouth’s Hitchcock Medical Center and the University of Sherbrooke to develop a microRNA-based diagnostic test to aid the detection of pancreatic cancer from fine-needle aspirate (FNA) biopsies.

1 Feb 2010

Ipsen reports consolidated group sales of €1,032.8M for 2009

Ipsen reported today its sales for the fourth quarter and full year 2009.

1 Feb 2010

Enzo Biochem generating more than $100M in revenues annually

Enzo Biochem, Inc. is well positioned to benefit from the results of its transformation involving acquisitions, new managements at each of its major subsidiaries and a heightened focus on new life science, diagnostic and therapeutic products, Barry Weiner, President, told the annual meeting of shareholders today.

30 Jan 2010

Society publication strengthens oncology journals program

Beginning this year, Springer will add the Journal of Cancer Education (JCE) to its journals publishing program. Published on behalf of the American Association for Cancer Education and the European Association for Cancer Education, the quarterly journal features a varied editorial board made up of MDs and PhDs who support the dissemination of information on improving cancer education worldwide.

30 Jan 2010

Oncology News and Research

Further Reading

Study could provide potential therapeutic strategies for treating prostate cancer

EpiCept regains compliance with Nasdaq minimum bid price requirement

VIDAZA prolongs survival in AML patients

GenSpera’s G-115 anti-cancer drug awarded US patent

Gentag signs license agreement to develop and commercialize post surgery wireless skin patch

Vantia Therapeutics initiates Phase IIb trial of VA106483 for nocturia

RECOTHROM topical hemostat exhibits low rate of anti-product antibody formation

Cytheris broadens patent protection for recombinant human interleukin-7

Spectrum Pharmaceuticals signs co-development and commercialization agreement with TopoTarget A/S

MDLinx announces new Omnibus offering for international pharmaceutical market research

ADT can worsen heart risk factors and may increase the risk of heart attack

BRI partners with French Government to create therapeutic antibodies for treatment of major diseases

IMRT and extensive safety measures can prevent radiation injuries in cancer patients, says oncology expert

Cephalon to acquire Swiss-based pharmaceutical company

Abbott signs licensing agreement with Pierre Fabre SA to develop and commercialize cancer antibody h224G11

Managing Myeloma reviews past accomplishments; discusses future goals in evolving therapeutic landscape

Asuragen enters into research agreements to develop microRNA-based diagnostic test

Ipsen reports consolidated group sales of €1,032.8M for 2009

Enzo Biochem generating more than $100M in revenues annually

Society publication strengthens oncology journals program

Cancer Research eBook

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News